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A novel missense mutation of COL5A2 in a patient with
Ehlers–Danlos syndrome
Miki Watanabe1,3, Ryuji Nakagawa2,3, Takuya Naruto1, Tomohiro Kohmoto1, Ken-ichi Suga2, Aya Goji2, Shoji Kagami2,
Kiyoshi Masuda1 and Issei Imoto1
Ehlers–Danlos syndrome (EDS) is a group of inherited connective tissue disorders characterized by hyperextensible skin, joint
hypermobility and soft tissue fragility. For molecular diagnosis, targeted exome sequencing was performed on a 9-year-old male
patient who was clinically suspected to have EDS. The patient presented with progressive kyphoscoliosis, joint hypermobility and
hyperextensible skin without scars. Ultimately, classical EDS was diagnosed by identifying a novel, mono-allelic mutation in COL5A2
[NM_000393.3(COL5A2_v001):c.682G4A, p.Gly228Arg].
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Ehlers–Danlos syndrome (EDS) is a heritable connective tissue
disorder characterized by a varying degree of skin hyperextensi-
bility, joint hypermobility and generalized connective tissue
fragility.1 According to the Villefranche nosology, there are six
subtypes of EDS that are classified on the basis of their clinical,
biochemical and molecular characteristics: classical, hypermobile,
vascular, kyphoscoliosis, arthrochalasia and dermatosparaxis.2
Accurate EDS diagnosis allows for appropriate screening of life-
altering complications, including vascular and hollow organ
rupture, and ligamentous laxity, leading to chronic dislocation
with subsequent pain and long-term disability.3 The various forms
of EDS are diagnosed on the basis of the patient’s clinical
presentation and family history. However, because of overlapping
symptoms, diagnosing EDS remains a challenge, and many
patients are left undiagnosed or have a delayed diagnosis. These
cases may remain uncategorized, even by well-trained medical
professionals.4,5
Mutations in genes encoding fibrillar (type I, III and V) collagen
chains or proteins have been identified in most types of EDS, with
the exception of the hypermobility type. These known underlying
genetic defects are different in each subtype.5 Genetic testing may
be diagnostically useful to identify specific EDS subtypes, but even
in typical cases, genetic defects are not always detected in
disease-causing genes.5–7 Because of shared clinical features
between EDS subtypes, the diagnosis of these rare conditions is
difficult, and an accurate diagnosis using the appropriate genetic
test for each subtype can be challenging. For a molecular
diagnosis outside the expected EDS genotype–phenotype rela-
tionship, simultaneous testing for multiple potential disease-
causing genes in the suspected EDS patient may be an effective
and systematic approach. Conventional Sanger sequencing has
routinely been used for genetic testing to identify disease-causing
mutations; however, it is laborious, expensive and time consuming
for multiple candidate genes.8 Recently, targeted exome sequen-
cing (TES) of candidate or known disease-associated genes
utilizing next-generation sequencing (NGS) technology has been
used to diagnose patients with various types of disorders,
including EDS.8 Here we report a de novo mono-allelic missense
mutation of COL5A2 (MIM 120190), NM_000393.3(COL5A2_v001):
c.682G4A, detected in a TES panel for the coding regions of 4,813
clinical phenotype-associated genes, including EDS-associated
genes, in a Japanese patient with EDS. Through this approach,
the patient was diagnosed with classical EDS (cEDS).
The patient is the fifth child of healthy, non-consanguineous
parents. After an uneventful pregnancy, he was born at 35 weeks
gestation following the premature rupture of the fetal mem-
branes. His birth weight was 1,924 g (−1.3 SD). Because of an
unknown cause, perforation of the terminal ileum occurred at the
age of 2 days, and an ileostomy was performed. After follow-up
with central venous nutrition and tube feeding, closure of the
ileostomy was performed at the age of 52 days, and he left the
hospital at the age of 73 days. He achieved head control at the age
of 9 months and walked independently at the age of 18 months.
At the age of 1 year, the patient was diagnosed with hypotonia
and kyphoscoliosis, and treated with a brace at another clinic. His
kyphoscoliosis was non-responsive to the brace and increased in
severity over time. At the age of 9 years, the patient was suspected
to have a connective tissue disorder because he showed muscle
weakness and joint hypermobility. Therefore, he was readmitted
to our hospital for diagnosis. Clinical examination at the age of 9
years showed a boy with a height of 117.4 cm (–2.3 SD) and
weight of 19.9 kg (–1.5 SD). He had joint hypermobility (Beighton
score = 6), mild hyperextensible skin (~1.5 cm on the volar surface
of the forearm) and severe kyphoscoliosis (Figure 1), but did not
have widened atrophic scars. In the minor diagnostic criteria for
cEDS, smooth velvety skin, muscle hypotonia and delayed gross
motor development were observed in addition to the manifesta-
tions of tissue extensibility and fragility (perforation of the
terminal ileum at the age of 2 days). No abnormality was revealed
during physical examination of the chest and abdomen or during
an ophthalmological evaluation. Echocardiography and
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abdominal ultrasound were normal. No family history of EDS was
observed. On the basis of his clinical presentation, the patient was
suspected of having cEDS (MIM 130000), kyphoscoliotic EDS
(MIM 225400) or other related minor EDS types in which severe
progressive kyphoscoliosis is prominent.2,5,7
Molecular diagnosis was performed on genomic DNA extracted
from a blood sample after informed consent was obtained from
the parents. The study was approved by the Ethics Committee at
Tokushima University. To screen multiple EDS genes and other
known disease-associated genes, we first performed TES for the
proband by using a TruSight One Sequencing Panel (Illumina, San
Diego, CA, USA) and MiSeq benchtop sequencer (Illumina) with
our pipeline for NGS data analysis, as described previously.9,10 To
identify presumably pathogenic single-nucleotide variants, we
excluded minor sequence variants with relatively high-allele
frequencies, i.e., 40.01, included in the 1000 Genomes Project
database (http://www.1000genomes.org/), NHLBI GO Exome
Sequencing Project (ESP6500, http://evs.gs.washington.edu/EVS/),
Human Genetic Variation Database11 (HGVD, http://www.genome.
med.kyoto-u.ac.jp/SnpDB/) and Integrative Japanese Genome
Variation Database12 (iJGVD, https://ijgvd.megabank.tohoku.ac.jp/).
The detection of copy-number variations using TES data with a
resolution of a single exon to several exons, depending
on the exon size, was performed as described previously.13
These analyses identified a mono-allelic, missense mutation,
NM_000393.3(COL5A2_v001):c.682G4A, in exon 9 of COL5A2,
which resulted in a Gly to Arg substitution at codon 228
[NM_000393.3(COL5A2_i001):p.(Gly228Arg)]. This result was
confirmed by using Sanger sequencing and was not found in
the parents (Figure 2a). Primer sequences are available upon
request. This mutation is not present in human genome variation
databases, such as dbSNP138, 1000 Genomes Project, ESP6500,
HGVD and iJGVD, or in disease-causing mutation databases, such
as the Human Gene Mutation Database Professional 2016.1
(HGMD, http://www.hgmd.org/), Leiden Open Variation Database
(LOVD, https://eds.gene.le.ac.uk/home.php?select_db =COL5A2)
and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/). No other
potentially pathogenic single-nucleotide variants or CNAs were
detected in the genes possibly responsible for EDS or other
related diseases. Through in silico analysis using LJB23 databases
for non-synonymous variant annotation in ANNOVAR
(http://annovar.openbioinformatics.org/en/latest/), this mutation
was predicted to damage protein function, i.e., SIFT score = 0,
PolyPhen-2 score = 1 and MutationTaster score = 1. The presence
of Gly at every third residue (Gly-X-Y) is considered to be essential
for the formation of the characteristic collagen triple helix
Figure 1. Anteroposterior (a) and lateral (b) radiographs of the patient.
Figure 2. (a) Electropherogram of COL5A2 (NM_000393.3) exon 9
and intron 9 sequences in the DNA of the patient and his parents.
The arrowhead denotes the position of the mutated base
(NM_000393.3:c.682G4A) in the patient. The DNA and correspond-
ing amino acid sequences of the wild type and mutant COL5A2
alleles are also shown. (b) Alignment of the COL5A2 amino acid
sequence around codon 228 in different mammalian species. The
arrowhead denotes the position of the p.Gly228Arg mutation. The
dots indicate the conserved Gly of the (Gly-X-Y)n repeat in the
collagen triple helix. The amino acids that are not matched with
those in Homo sapiens are depicted in light gray.
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(Figure 2b). Furthermore, Arg is one of the destabilizing residues
observed in the Gly position of the Gly-X-Y repeating pattern in
the collagen triple helix, and its presence may cause a range of
heritable connective tissue disorders.14 In the HGMD 2016.1 and
LOVD databases, the replacement of one Gly in the (Gly-X-Y)n
repeat by Arg was reported in four out of five (80%) and five out of
seven (71%) COL5A2 missense mutation cases with EDS,
respectively. The results of the molecular diagnosis suggested
that this is a de novomutation responsible for EDS, and the patient
was diagnosed with de novo cEDS.
In cEDS, more than 100 distinct COL5A1 mutations have been
described, but only 19 and 24 COL5A2 distinct mutations are
reported in the HGMD professional 2016.1 and LOVD databases,
respectively. Although COL5A1 mutations are scattered throughout
the gene, most COL5A2 mutations are located within the triple-helix
domain.7,15 Defects in COL5A1 are most commonly null mutations
consisting of either nonsense, frameshift or splice-site mutations
that generate a premature termination codon (PTC). These PTCs
encode transcripts that cause rapid degradation through nonsense-
mediated mRNA decay and consequently reduce production of type
V collagen7,15 In contrast, nearly all of the COL5A2 mutations
reported to date represent structural mutations, including missense
or in-frame exon-skipping splice mutations, thus resulting in the
production of mutant α2(V)-chains that probably incorporate into
collagen molecules and interfere with the formation of hetero-
trimers.7,15 Secreted mutant heterotrimers are predicted to exert a
dominant negative effect that causes functional haploinsufficiency.
Because no heterozygous COL5A2 null-allele mutations have been
reported, it is possible that COL5A2 null-allele mutations result in no
clinical phenotype of cEDS.7 Although similar observations were
reported in COL1A2 and COL11A1 in other connective tissue
disorders,16,17 the sample size of COL5A2 mutations needs to be
increased to conclude this hypothesis.
No clear genotype–phenotype correlations for type V collagen
defects have emerged in patients with cEDS.16 The large inter- and
intrafamilial phenotypic variabilities in cEDS and the possibility of
the presence of a COL5A1 null allele in individuals with only minor
symptoms of cEDS are also known.18 It has been reported that
20% of patients with cEDS who fulfilled all three criteria presented
with severe progressive kyphoscoliosis, whereas none of the
patients who fulfilled only two criteria presented with this
phenotype.7 Here, however, the patient fulfilled only two major
criteria of the Villefranche nosology and showed progressive
kyphoscoliosis. Compared with COL5A1 mutation carriers, COL5A2
mutation carriers have been reported to fall within the more
severe end of the phenotypic spectrum of cEDS, although no
difference in severity has been noted in patients carrying a null
mutation in one COL5A1 allele compared with patients carrying a
structural mutation in COL5A1 or COL5A2.18–20 Studies involving
an increased number of patients with COL5A2 mutations are
needed to clarify the genotype–phenotype correlations for type
V collagen defects in patients with cEDS.
HGV DATABASE
The relevant data from this Data Report are hosted at the Human
Genome Variation Database at http://dx.doi.org/10.6084/m9.fig
share.hgv.848 (2016).
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